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Abstract
Objective—Anxiety is commonly endorsed in Parkinson’s disease (PD) and significantly affects 
quality of life. The Beck Anxiety Inventory (BAI) is often used but contains items that overlap 
with common PD motor symptoms (e.g., “hands trembling”). Because of these overlapping items, 
we hypothesized that PD motor symptoms would significantly affect BAI scores.
Methods—One hundred non-demented individuals with PD and 74 healthy control participants 
completed the BAI. PD motor symptoms were assessed by the Unified Parkinson’s Disease Rating 
Scale (UPDRS). Factor analysis of the BAI assessed for a PD motor factor, and further analyses 
assessed how this factor affected BAI scores.
Results—BAI scores were significantly higher for PD than NC. A five-item PD motor factor 
correlated with UPDRS observer-rated motor severity and mediated the PD-control difference on 
BAI total scores. An interaction occurred, whereby removal of the PD motor factor resulted in a 
significant reduction in BAI scores for PD relative to NC. The correlation between the BAI and 
UPDRS significantly declined when controlling for the PD motor factor.
Conclusions—The results indicate that commonly endorsed BAI items may reflect motor 
symptoms such as tremor instead of, or in addition to, genuine mood symptoms. These findings 
highlight the importance of considering motor symptoms in the assessment of anxiety in PD and 
point to the need for selecting anxiety measures that are less subject to contamination by the motor 
effects of movement disorders.
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1. Introduction
Anxiety is prevalent in Parkinson’s disease (PD) and has a significant impact on quality of 
life [1]. The neuropathology of PD gives rise to anxiety—that is, it is intrinsic to the disease 
[2]—and the individual’s response to progressive disease symptoms may additionally elicit 
or exacerbate mood dysfunction [3]. Anxiety may occur independently of motor symptoms 
[4] or may occur simultaneously [5]. Disease-specific anxiety can develop, such as 
apprehension toward physical symptoms (e.g., freezing of gait) or the stigma of being 
perceived as physically disabled [6]. Such experiences may compound the limitations that 
the disease imposes on independence and quality of life (e.g., social withdrawal) [7]. Mood 
disorders in PD are underdiagnosed [8] and there are few treatments [2].
Misinterpreting anxiety symptoms as PD motor symptoms, or vice versa, can raise the risk 
of mismanaging the complex symptomatology of PD. For example, anxiety measures often 
contain items that can represent either genuine mood symptoms, or motor or other physical 
symptoms of PD -- muscle tension, fatigue, concentration deficits, sleep difficulties, 
shakiness. In the normative samples from which these measures were derived, such 
symptoms are typically consequences of mood disturbances. In PD, these symptoms may 
manifest independently of mood, or may occur in conjunction with mood disturbances. 
Accordingly, common anxiety measures may inaccurately assess mood symptoms in PD, 
and despite their widespread use in research and clinical evaluations, they lack clinimetric 
support for use in PD (reviewed in Leentjens et al., 2008) [9].
The purpose of this study was to assess the impact of motor symptoms on self-reported 
anxiety in mild to moderate PD. The Beck Anxiety Inventory (BAI) [10] is a standard 
measure of anxiety that was developed with the intention of reliably distinguishing anxiety 
from mood disorders in a psychiatric population (i.e., discriminant validity). The BAI has 
been widely used to assess anxiety in this disorder, and concerns have been raised regarding 
construct validity and potential under-recognition of anxiety in PD [11]. Considering the 
widespread use of the BAI, an understanding of the impact of motor symptoms on self-
reported anxiety would either increase confidence in its continued use or instead promote the 
selection of more PD-specific anxiety measures.
We hypothesized that a factor analysis of the BAI would reveal a PD motor factor consisting 
of items that also reflect hallmark motor symptoms, and that endorsement of motor 
symptoms would affect self-reported anxiety scores. We expected that tremor severity would 
impact BAI scores, and that BAI motor items would be significantly more elevated for those 
with moderate to severe tremor than for those with absent or mild tremor. We also assessed a 
group of age-matched individuals without PD in order to ask the question of whether anxiety 
in PD was still elevated after considering the motor items on the measure.
2. Methods
2.1 Participants
We assessed 100 individuals with idiopathic PD (45 women, 55 men) and 74 age- and 
education- matched normal control adults (NC) (42 women, 32 men) (Table 1). All 
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procedures were approved by the Institutional Review Board of Boston University, and 
consent was obtained according to the Declaration of Helsinki.
PD participants were recruited through the Parkinson’s Disease Clinic at Boston Medical 
Center and through other community resources including Fox Trial Finder and PD support 
groups. NC participants were recruited from the general community. For both groups, 
exclusion criteria included coexisting serious chronic illness (including psychiatric or 
neurological); use of psychoactive medications besides antidepressants and anxiolytics in the 
PD group; use of any psychoactive medication in the NC group; history of intracranial 
surgery, traumatic brain injury, and alcoholism or other drug abuse. All participants scored 
above 26 on the modified form of the Mini-Mental State Examination [12], on conversion to 
standard MMSE scoring.
Diagnosis of idiopathic PD was made by the participants’ neurologists, using United 
Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria [13]. The 
participants met clinical criteria for mild to moderate disease, with a modified Hoehn and 
Yahr stage range of 1–3 [14]. The sample included 13 in stage 1, 17 in stage 1.5, 37 in stage 
2, 15 in stage 2.5, and 18 in stage 3. Disease severity was assessed with the Unified 
Parkinson’s Disease Rating Scale [15, 16]. The mean UPDRS total score was 37.1 (SD = 
15.3), with a mean motor score of 21.4 (SD = 10.3). Average disease duration was 6.1 years 
(SD = 4.3). Levodopa equivalent dosages (LED), available for all participants with PD, were 
calculated according to Tomlinson and colleagues’ conversion formulae [17]. All 
participants were tested in the “on” medication state. Subjective quality of life was measured 
with the 39-item Parkinson’s Disease Questionnaire [18]. The participants completed the 
UPDRS at the same time as completing the self-report questionnaires.
For both the PD and NC groups, mood was assessed with the Beck Anxiety Inventory [10] 
and the Beck Depression Inventory-II [19]. No participant had a clinical diagnosis of 
anxiety.
2.2 Procedures
Participants completed self-report questionnaires at Boston University’s Vision and 
Cognition Laboratory:
Beck Anxiety Inventory (BAI): Standard 21-item anxiety measure (Beck & Steer, 
1990).
Beck Depression Inventory (BDI): Standard 21-item depression measure (Beck, 
Steer, & Brown, 1996).
Parkinson’s Disease Questionnaire-39 (PDQ-39): Standard 39-item measure of 
subjective quality of life in PD (Peto, Jenkinson, Fitzpatrick, & Greenhall, 1995).
Unified Parkinson’s Disease Rating Scale (UPDRS): Standard measure of PD 
severity assessing: (A) Mentation, Behavior, and Mood; (B) Activities of Daily 
Living (ADL); (C) Motor Examination (observer rated); (D) Complications (Fahn & 
Elton, 1987; Levy et al., 2005).
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To assess tremor symptoms, UPDRS tremor item (item #16) was used to characterize 
participants who reported absent-to-slight tremor (score of 0 or 1; n = 65) or moderate-to-
severe tremor (score of 2 or 3; n = 35). The UPDRS tremor items from the objective motor 
examination (items 20–26) were summed and used as a continuous measure for analyses.
2.3 Statistical analyses
To assess the loading of PD motor symptoms, a factor analysis was conducted with principal 
axis factor and varimax rotation.
Items were considered if they had a coefficient greater than .40 [20]. We hypothesized that 
BAI symptoms that represented motor symptoms of PD (shaky, hands trembling, unsteady) 
would load onto the same factor.
To assess the impact of these motor items on self-reported mood, comparisons were made 
between the total score and the total score minus PD motor symptoms (i.e., BAI modified). 
The following procedures were used to determine the impact of these motor items on mood 
scores:
A mixed design repeated measures ANOVA with one between group variable (PD vs NC) 
and one within group variable (BAI total vs BAI modified) was used, with specific interest 
in the interaction effect. If motor items had a greater impact on total scores from PD than 
from NC, removal of these items would result in a significant interaction. The same analysis 
was conducted according to tremor severity (absent-slight tremor vs. moderate-severe 
tremor) to assess whether tremor severity had an impact on self-reported anxiety specifically 
for PD.
Mediation analyses were conducted with the SPSS mediation modelling software, 
PROCESS [21], to consider whether motor-like items mediated the difference between PD-
NC on total mood scores. The analysis considered the total effect of group on anxiety (BAI), 
and the indirect effect mediated by BAI motor items. A bootstrap estimation approach with 
1,000 samples was used to measure the indirect effect [22], with 95% confidence intervals. 
The indirect effect was considered significant when the 95% confidence intervals did not 
contain zero [23]. A significant mediator was indicated when the total effect was significant, 
the indirect effect was significant, and the confidence intervals of the direct effect contained 
zero [21].
For PD only, one-tailed Pearson correlations were used to assess the relation between BAI 
motor symptoms and the following disease characteristics: 1) objective tremor severity 
(UPDRS #20–26), 2) UPDRS motor severity (UPDRS Section C), 3) disease severity 
(H&Y), 4) quality of life (PDQ-39), 5) depression (BDI-II), and 6) disease duration. To 
account for multiple comparisons, alpha was set at .01. Follow-up partial correlations were 
conducted, controlling for motor-like symptoms, and Fishers r-to-z transformations were 
conducted to determine if controlling for motor symptoms had a significant impact on the 
relation between mood and disease characteristics. Analyses were performed with SPSS 
18.0 (SPSS, Inc., Chicago, IL).
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3. Results
The BAI factor analysis yielded a 5-factor solution, cumulatively accounting for 47.2% of 
the variance in the BAI. Three items were not included in the analysis: “numbness” and 
“feelings of choking” did not reach a coefficient of .4, and none of the participants endorsed 
“terrified”. The PD motor items that were selected a priori for consideration loaded onto the 
first factor, which accounted for 11.3% of the variance in the BAI. The five factors consisted 
of the following BAI items:
[Factor 1]: Shaky, hands trembling, unsteady, wobbliness in legs, nervous
[Factor 2]: Scared, fear of the worst, fear of dying
[Factor 3]: Faint, dizzy or lightheaded, fear of losing control, heart pounding
[Factor 4]: Sweating, feeling hot, face flushed
[Factor 5]: Indigestion, unable to relax, difficulty breathing
3.1 Interaction Effect: BAI by Group
Removing the BAI motor factor resulted in a significant reduction in the BAI for both PD 
[t(99) = 13.54, p < .0001] and NC [t(73) = 4.89, p < .0001], but the reduction was 
significantly greater for PD than NC [F(1, 172) = 86.88, p < .0001, η2 = .34] (Figure 1). PD 
had higher scores than NC on BAI total [t(164.16) = 8.03, p < .0001], the BAI motor factor 
[t(133.81) = 10.39, p < .0001], and the BAI modified [t(171.36) = 4.93, p < .0001].
We compared BAI scores for those with absent-slight vs. moderate-severe tremor (UPDRS 
tremor item). Removing the BAI motor factor resulted in a significant reduction in the BAI 
in both PD groups: absent-slight tremor [t(64) = 10.02, p < .0001] and moderate-severe 
tremor [t(34) = 9.84, p < .0001]. The reduction was significantly greater for those with 
moderate-severe tremor [F(1, 98) = 7.73, p < .007, η2 = .07]. Those with moderate-severe 
tremor had higher scores on the BAI motor factor [t(98) = 2.82, p < .006] but did not differ 
from the absent-slight tremor group on BAI total [t(98) = 1.34, p < .18] or BAI modified 
[t(98) = .172, p < .86].
3.2 Mediation Analysis
The results of the mediation analysis are presented in Table 2. When the BAI motor factor 
was entered as a mediator of group and BAI total scores, the total effect was significant [β = 
−4.78, p < .0001], the indirect effect was significant [β = −4.23, 95% CI: −5.60, −3.15], and 
the direct effect approached zero [β = −0.54, 95% CI: −1.63, .55]. That is, the BAI motor 
factor fully mediated the effect of PD on BAI total scores.
3.3 Correlations: Mood and Disease Characteristics
BAI total score correlated significantly with poorer quality of life (PDQ-39), higher BDI-II 
scores, and longer disease duration (Table 3). There were additional trends for correlations 
of BAI total score with poorer motor function (UPDRS motor score) and with tremor 
severity (sum of tremor items from the UPDRS motor section). The BAI motor factor related 
to tremor severity, poorer motor function, poorer quality of life, and greater depression. 
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There were additional trends for correlations with greater disease severity and greater 
disease duration.
For the partial correlations controlling for the BAI motor factor, the correlation remained 
significant between the BAI and quality of life, depression severity, and disease duration. 
Fisher’s r-to-z transformations indicated that the difference in the size of the correlation was 
significant for the relation between BAI and tremor severity, motor function, quality of life, 
and disease severity.
4. Discussion
The results of this study addressed the impact of motor symptoms on self-reported anxiety. 
As hypothesized, PD motor symptoms grouped together on factor analysis of the BAI. The 
BAI motor factor significantly correlated with disease characteristics – tremor severity, 
motor function (UPDRS), quality of life, and depression. The BAI total score correlated with 
poorer quality of life, higher BDI-II scores, and longer disease duration. Controlling for the 
BAI motor factor resulted in a significant decrease in the strength of the correlation between 
the BAI and quality of life.
The impact of the BAI motor factor on BAI total scores highlights the importance of 
considering motor symptoms when measuring self-reported anxiety. After removing the BAI 
motor factor, the PD group showed a significantly greater decrease in BAI scores than did 
NC. As expected, tremor severity related to symptom report on the BAI motor factor; for 
individuals with moderate or severe tremor, the removal of BAI motor items had a 
significantly greater impact on the anxiety score than for those with absent or slight tremor. 
The BAI motor factor mediated the effect of PD on anxiety. Though PD is associated with 
greater anxiety disturbances than seen in the general population [1, 24], on the widely-used 
BAI the effect of PD was significantly influenced by their scores on motor items. BAI scores 
remained significantly higher for PD than NC even when accounting for motor items, 
however, indicating that the BAI does measure anxiety (apart from motor disturbances) in 
PD relative to a non-PD population. In another study that assessed the BAI in a sample of 
294 individuals with PD, a single 6-item affective factor was independent of motor or 
somatic symptoms [25].
The question remains as to whether those with PD erroneously endorse motor symptoms as 
mood symptoms, or whether they are endorsing genuine mood disturbance on these motor 
items, or whether there is an interaction between mood and motor symptoms. It is possible 
that these motor symptoms operate independently of mood and offer a more general index of 
disease severity. It is also possible that the motor symptoms operate in conjunction with 
mood, exacerbating or causing mood disturbances. For example, the manifestation of motor 
symptoms may promote social withdrawal [3], thereby promoting anxiety and depression. 
Interactive motor-mood effects such as anxiety related to motor fluctuations may affect 
motor and mood disturbance [5]. Future work is needed in order to address these questions 
of causes, mechanisms, and treatment targets. In particular, a wider range of individuals 
should be sampled than are described in the present study, which was limited to participants 
with mild to moderate PD who did not have a clinical diagnosis of a mood disorder. 
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Nevertheless, PD motor symptoms significantly contributed to anxiety scores in this sample, 
suggesting that their impact may be even stronger in a sample with more severe disease.
The complexity of motor-mood symptoms in PD is noteworthy in its potential contribution 
to how the disease is understood and managed. Misinterpretation of mood symptoms may 
result in symptom mismanagement. For example, there are a host of adverse side effects 
associated with pharmacological treatments for neuropsychiatric symptoms in PD [26], and 
unnecessarily introducing such treatments may have a negative impact on quality of life. In 
contrast, misinterpreting mood as motor symptoms may result in entirely overlooking mood 
symptoms. One study of 362 individuals with PD found that clinicians who completed a 
self-report questionnaire on behalf of their patients endorsed less anxiety than individuals 
with PD who completed the same self-report questionnaire [27]. In this instance, failure to 
recognize mood symptoms in PD can result in untreated mood dysfunction, which is a 
significant determinant of quality of life.
Continued consideration of mood dysfunction in PD, and its measurement, is warranted in 
order to direct proper assessment, diagnosis, and treatment. Despite the well documented 
prevalence and burden of mood dysfunction in PD, there remains widespread use of mood 
measures lacking psychometric validation for PD. The Movement Disorders Society has 
noted that popular anxiety scales lack sufficient psychometric properties for use in PD and 
can only be classified as “suggested” rather than “recommended” measures of mood in this 
population [9]. It has more recently been suggested that the BAI and the Hamilton Anxiety 
Rating Scale together provide a valid, multi-domain assessment of anxiety including 
generalized anxiety, non-specific somatic symptoms, respiratory symptoms, and 
cardiovascular symptoms [28]. Leentjens et al. (2014) extended this work by creating the 12-
item Parkinson’s Anxiety Scale [27] to assess persistent anxiety, episodic anxiety, and 
avoidance behavior; the items assessing persistent and episodic anxiety were found to have 
acceptable reliability and validity. The Parkinson’s Anxiety Scale showed better reliability 
than the BAI [29], and was found to be more suitable for assessing anxiety in PD [30]. The 
results of the present study further demonstrate the importance of employing mood measures 
specifically validated for individuals with PD; failure to do so may yield uninterpretable 
results, and ultimately raise the risk of mismanaging PD symptoms. Future research might 
consider determining the barriers to assessing mood with PD-specific measures. The use of 
valid measures and efficacious treatments for mood dysfunction will have important 
implications for the care of individuals with PD and for the enhancement of their quality of 
life.
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Highlights
• The Beck Anxiety Inventory (BAI) assesses Parkinson’s disease (PD) motor 
symptoms.
• Hallmark PD motor symptoms loaded onto one factor, and affected BAI 
scores.
• BAI scores significantly declined when PD motor items were removed.
• Motor items mediated the BAI difference between PD and normal control 
participants.
• PD anxiety assessments should distinguish between motor and mood 
symptoms.
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Figure 1. 
Interaction: BAI by Group
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